Veracyte Q4 revenue $98.2M (+22% YoY); full-year $361.1M (+22%)

VERACYTE, INC.

2023-FY EPS reported -$1.02 revenue$361,051,000

Q4 2023 revenue $98.2M, up 22% YoY; testing revenue $90.4M (+29%).
Full-year 2023 revenue $361.1M, up 22%; total test volume 126,977 (+24%).
Net loss $28.3M ($0.39/share) includes $32M impairment; non-GAAP gross margin 70%.
Generated $44M cash from operations in FY2023; cash on hand $216M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

VERACYTE, INC. reported financial results for the quarter and year ended December 31, 2023.

Period: the quarter and year ended December 31, 2023
Result: reported results

Exact text from the filing

On February 22, 2024, Veracyte, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2023. The full text of the press release is furnished as Exhibit 99.1 to this report.

View on SEC.gov

710 earnings releases filed in the last 30 days. Browse all earnings releases →

VERACYTE, INC. filing history →

Source: SEC EDGAR

accession 0001384101-24-000013

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.